Actemra Drug Market is segmented By Route of Administration (Intravenous, Subcutaneous), By End User (Hospitals, Clinics, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Dimensione del Mercato in USD Bn
CAGR8.5%
Periodo di Studio | 2024 - 2031 |
Anno di Base per la Stima | 2023 |
CAGR | 8.5% |
Concentrazione del Mercato | High |
Principali Attori | Hoffmann-La Roche, Genentech, Novartis, Biogen, Sanofi and Among Others. |
The Actemra drug market is estimated to be valued at USD 3.796 Bn in 2024 and is expected to reach USD 6.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031. The prevalence of rheumatoid arthritis, the primary disease targeted by Actemra, has been increasing worldwide. Additionally, strong efficacy results have encouraged more physicians to prescribe Actemra as a first-line treatment option.